Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PPAR-gamma in Cushing's disease.

Anthony P Heaney1

  • 1Division of Endocrinology, Cedars-Sinai Research Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, California 90048, USA. HeaneyA@cshs.org

Pituitary
|January 18, 2006
PubMed
Summary

Cushing's disease, often caused by small pituitary tumors secreting ACTH, leads to severe health issues. Novel PPAR-gamma ligands show promise for new treatments targeting tumor growth.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiometabolic Risk Parameters in "Nonfunctioning" Adrenal Incidentalomas: A Systematic Review and Meta-analysis.

The Journal of clinical endocrinology and metabolism·2025
Same author

A Bridge Too Far? Towards Medical Therapy for Clinically Nonfunctioning Pituitary Tumors.

International journal of molecular sciences·2025
Same author

Genetic profiling of synchronous pituitary corticotroph adenomas.

Pituitary·2025
Same author

Revised European Society of Endocrinology Clinical Practice Guideline for the management of aggressive pituitary tumours and pituitary carcinomas.

European journal of endocrinology·2025
Same author

Reduced IGF-1 Levels Following Clomiphene Treatment for Male Hypogonadism.

Journal of the Endocrine Society·2025
Same author

Genetic Profiling of Synchronous Pituitary Corticotroph Adenomas.

Research square·2025

Area of Science:

  • Endocrinology
  • Oncology
  • Pharmacology

Background:

  • Cushing's disease results from excess ACTH secretion by pituitary tumors, causing significant morbidity and mortality.
  • Current treatments like surgery and radiation have limited success rates and considerable side effects.
  • Existing medications manage hypercortisolism but do not address pituitary tumor growth.

Purpose of the Study:

  • To explore novel therapeutic strategies for Cushing's disease.
  • To investigate the potential of peroxisome-proliferator activating receptor-gamma (PPAR-gamma) ligands as a treatment.

Main Methods:

  • In vitro and in vivo studies using Cushing's disease models.
  • Evaluation of novel PPAR-gamma ligands for therapeutic potential.

Main Results:

  • PPAR-gamma ligands demonstrated potential utility in preclinical models of Cushing's disease.
  • These findings pave the way for early clinical studies.

Conclusions:

  • Novel PPAR-gamma ligands represent a promising avenue for developing new therapies for Cushing's disease.
  • Further clinical investigation is warranted to assess their efficacy and safety.

Related Experiment Videos